Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
Bischof L, Ussmann J, Grimm J, Bill M, Brauer D, Backhaus D, Herrmann L, Merz M, Herling M, Metzeler KH, Franke GN, Vucinic V, Platzbecker U, Schwind S, Jentzsch M. Bischof L, et al. Among authors: backhaus d. Leukemia. 2024 Jan;38(1):198-201. doi: 10.1038/s41375-023-02072-y. Epub 2023 Oct 25. Leukemia. 2024. PMID: 37880479 Free PMC article.
ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.
Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S. Jentzsch M, et al. Among authors: backhaus d. Bone Marrow Transplant. 2021 Apr;56(4):936-945. doi: 10.1038/s41409-020-01129-1. Epub 2020 Nov 19. Bone Marrow Transplant. 2021. PMID: 33208914 Free PMC article.
Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Pointner R, Goldmann K, Schulz J, Niederwieser D, Platzbecker U, Schwind S. Jentzsch M, et al. Among authors: backhaus d. Am J Hematol. 2021 Jul 1;96(7):E237-E239. doi: 10.1002/ajh.26179. Epub 2021 May 5. Am J Hematol. 2021. PMID: 33811773 Free article. No abstract available.
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation.
Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Schulz J, Goldmann K, Niederwieser D, Platzbecker U, Schwind S. Jentzsch M, et al. Among authors: backhaus d. Blood Cancer J. 2021 Apr 29;11(4):80. doi: 10.1038/s41408-021-00471-x. Blood Cancer J. 2021. PMID: 33927190 Free PMC article. No abstract available.
Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
Jentzsch M, Grimm J, Bill M, Küpper J, Backhaus D, Brauer D, Schulz J, Franke GN, Vucinic V, Niederwieser D, Platzbecker U, Schwind S. Jentzsch M, et al. Among authors: backhaus d. Bone Marrow Transplant. 2021 Oct;56(10):2610-2612. doi: 10.1038/s41409-021-01407-6. Epub 2021 Jul 15. Bone Marrow Transplant. 2021. PMID: 34267355 Free PMC article. No abstract available.
28 results